Onyx has data showing that Sorafenib slows tumor growth, compared with a placebo, but in late-stage trials only 2% of patients had their tumors shrink enough to be counted in the response rate.
Flurizan completed Phase 2 human trials in Alzheimer's patients, and it is also in Phase 2-b human clinical trials for treating patients with pre-metastatic prostate cancer.